Ubenimex
DCTPepD ID DCTPepD0059
Active Ingredients Ubenimex
Description A microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Ubenimex competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage and bone marrow stem cell as well as stimulates release of interleukin-1 and -2, thus further enhances its antitumor activity.
Synonyms Bestatin; L-Leucine, N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-, [S-(R*,S*)]-; N-[(2S,3R)-4-phenyl-3-amino-2-hydroxybutyryl]-L-leucine; NK 421; [(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine; [S-(R*,S*)]-N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-L-leucine; Ubenimex
Disease Leukemia, Lung cancer, Nasopharyngeal cancer, Hypercholesterolaemia
Classification
Aminopeptidases inhibitor Peptide and derivative
Structure Information
Molecular Formula C16H24N2O4
Molecular Weight 308.37
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid
InChI InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1
InChI_Key VGGGPCQERPFHOB-RDBSUJKOSA-N
SMILES CC(C)C[C@H](NC([C@@H](O)[C@H](N)CC1=CC=CC=C1)=O)C(O)=O
External Codes
PubChem CID 72172
DrugBank Accession Number DB03424
NCI Thesaurus Code C1015
UNII I0J33N5627 GSRS
CAS 58970-76-6
Drug approval
Drug indication
An adjuvant therapy used for acute and chronic myelonous leukemia, lung cancer and nasopharyngeal cancer. It is also used to treat hypercholesterolaemia.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT02700529 | Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA) | Lymphedema | Phase 2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
